Biocon Sept qtr PAT seen down 14% at Rs 77cr: Dolat Capital

Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Biocon September quarter net sales are expected to go down by 30.1% at Rs 475 crore, year-on-year, (YoY) basis.

October 11, 2011 / 13:48 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Biocon September quarter net sales are expected to go down by 30.1% at Rs 475 crore, year-on-year, (YoY) basis. Notably, the estimated sales in Sep

first published: Oct 11, 2011 12:09 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347